National patterns of angiotensin-converting enzyme inhibitor use in congestive heart failure

Archives of Internal Medicine

Volumn 157, Issue 21, 1997, Pages 2460-2464

  Stafford, Randall S ^a   Saglam, Demet ^a   Blumenthal, David ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ARTICLE; CONGESTIVE HEART FAILURE; DRUG EFFECT; MEDICAL PRACTICE; PATIENT; PHYSICIAN; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL;

EID: 0030689748     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.157.21.2460     Document Type: Article

References (34)

1. O'Connell JB, Bristow MR. Economic impact of heart failure in the United States: time for a different approach. J Heart Lung Transplant 1994;13(suppl 4):S107-S112.
2. Schocken DD, Arrleta MI, Leaverton PE, Ross EA. Prevalence and mortality rate of congestive heart failure in the United States. J Am Coll Cardiol. 1992;20:301-306.
3. Garg R, Yusuf S. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure: Collaborative Group on ACE Inhibitor Trials. JAMA. 1995;273:1450-1456.
4. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
5. The CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study [CONSENSUS]. N Engl J Med. 1987;316:1429-1435.
6. Kleber FX, Niemoller L, Doering W. Impact of converting enzyme Inhibition on progression of chronic heart failure. Br Heart J. 1992;67:289-296.
7. Konstam MA, Rousseau MF, Kronenberg MW, et al. Effects of the angiotensin converting enzyme inhibitor enalapril on the long-term progression of ventricular dysfunction in patients with heart failure. Circulation. 1992;86:431-438.
8. Cohn JN. The management of chronic heart failure. N Engl J Med. 1996;335:490-498.
9. The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricle ejection fractions. N Engl J Med. 1992;327:685-691.
10. Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1992;327:669-677.
11. Levine TB, Olivari MT, Garberg V, Sharkey SW, Cohn JN. Hemodynamic and clinical response to enalapril, a long-acting converting-enzyme inhibitor, in patients with congestive heart failure. Circulation. 1984;69:548-553.
12. Guidelines for the evaluation and management of heart failure: report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Evaluation and Management of Heart Failure). Circulation. 1995;92:2764-2784.
13. Agency for Health Care Policy and Research. Heart Failure: Management of Patients With Left Ventricular Systolic Dysfunction. Rockville, Md: Agency for Health Care Policy and Research; 1994. Publication 94-0613.
14. Smith NL, Psaty BM, Pitt B, Garg R, Gottdiener JS. Temporal patterns in the medical treatment of congestive heart failure with ACE-inhibitors in older adults. Circulation. 1996;93:634. Abstract.
15. Cody RJ. Management of refractory congestive heart failure. Am J Cardiol. 1992;4:141-149.
16. Rajfer SI. The perspective of the pharmaceutical industry on the development of new drugs for heart failure. J Am Coll Cardiol. 1993;22(suppl):198A-200A.
17. Clarke KW, Gray D, Hampton JR. Evidence of inadequate investigation and treatment of patients with heart failure. Br Heart J. 1994;71:584-587.
18. Philbin EF, Andreaou C, Rocco TA, Lynch LJ, Baker SL. Patterns of angiotensin-converting enzyme Inhibitor use in congestive heart failure in two community hospitals. Am J Cardiol. 1996;77:832-838.
19. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med. 1996;156:2537-2541.
20. National Center for Health Statistics. Public Use Data Tape Documentation: 1989 National Ambulatory Medical Care Survey. Hyattsvllle, Md: National Center for Health Statistics; 1992.
21. National Center for Health Statistics. Public Use Data Tape Documentation: 1990 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics; 1992.
22. National Center for Health Statistics. Public Use Data Tape Documentation: 1991 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics; 1993.
23. National Center for Health Statistics. Public Use Data Tape Documentation: 1992 National Ambulatory Medical Care Survey. Hyattsville, Md: National Center for Health Statistics; 1994.
24. National Center for Health Statistics. Public Use Data Tape Documentation: 1993 National Ambulatory Medical Care Survey. Hyattsviile, Md: National Center for Health Statistics; 1995.
25. National Center for Health Statistics. Public Use Data Tape Documentation: 1994 National Ambulatory Medical Care Survey. Hyattsvllle, Md: National Center for Health Statistics; 1996.
26. International Classification of Diseases, Ninth Revision, Clinical Modification. 3rd ed. Washington, DC: Public Health Service, US Dept of Health and Human Services; 1989.
27. Schneider D, Appleton L, McLemore T. A reason for visit classification for ambulatory care: National Center for Health Statistics. Vital Health Stat 2. 1979;78:1-74.
28. National Center for Health Statistics. National Ambulatory Medical Care Survey: background and methodology, United States. Vital Health Stat 2. 1974;81:1-76.
29. Statistical Analysis System, SAS/STAT User's Guide, Version 6. 4th ed. Cary, NC: SAS Institute Inc; 1990.
30. Hosmer DW, Lemeshow S. Applied Logistic Regression. New York, NY: John Wiley& Sons Inc; 1989.
31. Baker DW, Konstam MA, Bottorff M, Pitt B. Management of heart failure, l: pharmacology treatment. JAMA. 1994;272:1361-1366.
32. Stafford RS, Blumenthal D, Pasternak RC. Variations in the cholesterol management practices of US physicians. J Am Coll Cardiol. 1997;29:140-147.
33. Wenneker MB, Epstein AM. Racial inequalities in the use of procedures for patients with ischemic heart disease in Massachusetts. JAMA. 1989;261:253-257.
34. Pearson TA, McBride PE, Miller NH, Smith SC. Task Force 8: organization of preventive cardiology service. J Am Coll Cardiol. 1996;27:964-1047.